Anthropic’s life sciences plans: Mystery programs, Nobel hires, M&A and big ambitionnews2026-07-20T15:37:57+00:00July 20th, 2026|Endpoints News|
Scribe’s $96M IPO; Scholar Rock awaits site classification for apitegromabnews2026-07-20T15:20:34+00:00July 20th, 2026|Endpoints News|
J&J, AbbVie said to have also looked at AtaiBeckley before Lilly’s $2.8B dealnews2026-07-20T15:03:25+00:00July 20th, 2026|Endpoints News|
UK biotech VC funding rebounds and reaches record highnews2026-07-20T11:23:41+00:00July 20th, 2026|Endpoints News|
Bristol Myers, Nvidia say they’ll build ‘most powerful’ AI supercomputer in pharmanews2026-07-20T10:59:51+00:00July 20th, 2026|Endpoints News|
Biogen’s mixed Alzheimer’s data; Two new startups launch; and morenews2026-07-18T10:00:14+00:00July 18th, 2026|Endpoints News|
Biogen’s mixed Alzheimer’s data; Two new startups launch; and morenews2026-07-18T10:00:14+00:00July 18th, 2026|Endpoints News|
Midsize biotechs press White House to drop CMS pricing rulesnews2026-07-17T18:42:39+00:00July 17th, 2026|Endpoints News|
Midsize biotechs press White House to drop CMS pricing rulesnews2026-07-17T18:42:39+00:00July 17th, 2026|Endpoints News|
Celcuity got its cancer drug approved. Then its stock dippednews2026-07-17T18:03:35+00:00July 17th, 2026|Endpoints News|
